CollPlant BiotechnologiesCLGN -2.46%35 PB Ratio is 1.00 as of Jul. 01, 2026, which is 61% below its 10-year median of 2.54. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, CollPlant Biotechnologies ranks better than 82.34% on this metric.
CollPlant Biotechnologies Ltd stock PB Ratio (=1.03) is close to 10-year low of 0.98.
The historical rank and industry rank for CollPlant Biotechnologies's PB Ratio or its related term are showing as below:
CLGN'
s PB Ratio Range Over the Past 10 Years
Min: 0.97 Med: 2.54 Max: 4.85
Current: 1
During the past 13 years, CollPlant Biotechnologies's highest PB Ratio was 4.85. The lowest was 0.97. And the median was 2.54.
CLGN's PB Ratio is ranked better than 82.34% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs CLGN: 1.00
During the past 12 months, CollPlant Biotechnologies's average Book Value Per Share Growth Rate was -68.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CollPlant Biotechnologies was 131.60% per year. The lowest was -45.20% per year. And the median was 2.70% per year.
Back to Basics: PB Ratio
CollPlant Biotechnologies (NAS:CLGN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CollPlant Biotechnologies PB Ratio Related Terms
CollPlant Biotechnologies PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CollPlant Biotechnologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CollPlant Biotechnologies (CLGN) has a PB Ratio of 1.00 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CollPlant Biotechnologies and its competitors. This is 61% below median its historical median of 2.54. Over the past decade, CollPlant Biotechnologies' PB Ratio has ranged from 0.97 to 4.85. According to the industry distribution chart, CollPlant Biotechnologies ranks #217 out of 1229 companies in the Biotechnology industry, placing it in the top 17.7%.
Is CollPlant Biotechnologies' PB Ratio too high?
CollPlant Biotechnologies' current PB Ratio of 1.00 is 61% below median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 4.85. The Biotechnology industry median PB Ratio is 2.87. CollPlant Biotechnologies' value of 1.00 is 65.2% below this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #217 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' PB Ratio compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #217 out of 1229 companies for PB Ratio. This places CollPlant Biotechnologies in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.87. CollPlant Biotechnologies' value of 1.00 is 65.2% below this benchmark. Historically, CollPlant Biotechnologies' own PB Ratio has ranged from 0.97 to 4.85 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 2.87, CollPlant Biotechnologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current PB Ratio of 1.00 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current PB Ratio is 1.00, which is 61% below median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current PB Ratio is 1.00, which is 61% below median its 10-year median of 2.54 and 65.2% below the Biotechnology industry median of 2.87. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current PB Ratio is 1.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
PB Ratio: 1.00 (61% below median its 10-year median of 2.54)
GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
Industry Position: 65.2% below the Biotechnology median (#217 of 1229)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
